CARA Therapeutics

By | May 5, 2017
Our New Ticker is: CARA
Good Morning Everyone,Should you be considering Cara Therapeutics? We think so! Here’s why…CARA stock has recently dropped in price, but there’s a good reason. Cara Therapeutics sold more than 5.1 million shares through a public offering in April. The shares tumbled on this dilution – which isn’t great news for current stockholders – but if you purchased recently or plan to do so, it’s very good news. The net proceeds from this was $86.5 million! This puts the company on solid footing into 2019. Current investors should be able to rest easy for a while.There are several important game-changers on the horizon for CARA: 

  • The company will announce top-line data from its phase 2b study of oral CR845 in treating chronic pain associated with osteoarthritis.
  • Cara also plans to report results from an interim conditional power analysis from a phase 3 study evaluating intravenous CR845 in treating post-operative pain.
  • On top of these two updates, it expects to get data from a pharmacokinetic safety trial of multiple doses of oral CR845 in hemodialysis patients. This data will help Cara define bioequivalent tablet strengths as part of its effort to develop an oral tablet formulation for moderate to severe uremic pruritus (itching caused by chronic kidney disease).

CR845 has done well in previous clinical studies, so the chances are high that it will do well again. Of course, this is something to keep an eye on.

What’s so special about CR845?:

The opioid epidemic in the US is a huge issue. Drugs like oxycodone, morphine, and hydrocodone are great for alleviating pain, but they are also highly addictive. So much so, that doctors are moving away from prescribing them, but what do they offer their patients instead? This is where CR845 could be poised to fill a growing void:

      • although CR845 is also an opioid,it doesn’t work the same as the others. Instead of binding with the mu receptors in the central nervous system, it targets kappa opioid receptors in peripheral nerve cells outside of the central nervous system.This means it

                        can alleviate pain without being addictive.

There is a huge potential market!

  • The market for acute pain managed outside the hospital setting in the United States exceeds 200 million prescriptions dispensed annually. 
  • The market for chronic pain treatments is extremely large estimated at over 100 million prescriptions annually.
  • There are over 20 million patients with chronic pruritus (itching) treated with prescription drugs in U.S. each year. Many of these patients still experience inadequate relief of their itching.

(Source: www.cara.com)

As with any investment, there are of course, risks. Problems could arise during clinical testing and the FDA could reject approval. One of the studies was in fact already put on hold – although the hold was already lifted.

CR845 PIPELINE

Do your research, but we definitely have this one on our radar!

Good Trading!

The Team

Company Profile:

Cara Therapeutics is a clinical-stage biotechnology company located in Stamford, CT focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed.  We aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors.
Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.


Press Releases:
Cara Therapeutics Reports First Quarter 2017 Financial Results
STAMFORD, Conn., May 04, 2017 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2017.”During the quarter, we were pleased to announce positive data from Part A of our Phase 2/3 trial of I.V CR845 in CKD-associated pruritus, where we observed sustained clinical benefit over the entire two-month treatment period, supporting the potential viability of I.V CR845 as a long-term therapeutic approach for this unmet medical need,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “In addition to completing a successful follow on offering to support operations into 2019, our other late-stage trials continue to enroll well, and we look forward to completing an interim assessment in our adaptive Phase 3 postoperative pain trial of I.V. CR845, as well as reporting data from our Phase 2b chronic pain trial of Oral CR845 this quarter.”
Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845
STAMFORD, Conn., April 24, 2017 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced summary results from its Phase 1 safety trial showing that I.V. CR845 did not significantly differ from placebo across three quantitative measures of respiratory drive in healthy individuals. Respiratory depression remains the most life-threatening side effect of traditional, centrally acting, opioid analgesics, the most commonly used drug class for current treatment of postoperative pain in the United States.